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Matrix metaloproteinases (MMPs) and their specific inhibitors - tissue inhibitors of 
matrix metalloproteinases (TIMPs) play an important role in pulmonary extracellular matrix 
destruction. Sarcoidosis is an inflammatory disease affecting multiple organs. It has been 
reported that MMP-9 and TIMP-1 levels were increased in bronchoalveolar lavage fluid and 
induced sputum of sarcoidosis patients. The aim of our study was to evaluate MMP-9, TIMP-1 
and MMP-9/TIMP-1 complex concentrations and MMP-9/TIMP-1 ratio in sarcoidosis patients, 
their relationship with inflammatory markers and their ability do predict the existence of 
disease. We included 101 sarcoidosis patients and 50 healthy subjects. Serum samples were 
analyzed. Besides routine biochemical parameters, high-sensitive C-reactive protein (hsCRP), 
serum amyloid A (SAA), MMP-9, TIMP-1 and MMP-9/TIMP-1 complex concentrations were 
measured. MMP-9 (P<0.05), hsCRP, SAA and TIMP-1 (P<0.001) concentrations were 
significantly increased in patients whereas MMP-9/TIMP-1 complex was higher in patients, but 
with marginal significance. In sarcoidosis, TIMP-1 correlated significantly positively with  
inflammatory parameters (P<0.05). Uni-variate analysis showed that MMP-9, TIMP-1, hsCRP 
and SAA had the ability to predict the existence of sarcoidosis. In the model consisted of MMP-
9, TIMP-1, hsCRP and SAA, only SAA remained significant predictor of disease (P<0.01). 
Results showed the significance of MMP-9 and TIMP-1 in sarcoidosis.  Keywords:  sarcoidosis; matrix metalloproteinase-9,  






Normal lung functions are supported by extracellular matrix (ECM). Abnormal 
remodelling and destruction of ECM occurs in many pulmonary diseases. It has been 
described that matrix metaloproteinases (MMPs), a family of zinc and calcium 
dependent endopeptidases (1) and their specific inhibitors - tissue inhibitors of matrix 
metalloproteinases (TIMPs) play an important role in pulmonary ECM destruction (1, 
2). TIMPs bind MMPs in a 1:1 manner to prevent their enzymatic activity (3). The 
expression of both MMPs and TIMPs is regulated by exogenous stimuli, cytokines, 
growth factors and cell-cell contact (2).  
Sarcoidosis is an inflammatory disease affecting multiple organs primarily lungs 
with diverse clinical course. Extensive ECM remodelling reported in these patients 
occurs as a consequence of granuloma formation common to all disease manifestations 
(2). Henry et al (4) and Fireman et al (5) found that MMP-9 levels were increased in 
bronchoalveolar lavage (BAL) fluid and induced sputum of sarcoidosis patients. 
Shimada et al (6) demonstrated increased TIMP-1 concentration in BAL fluid that was 
associated with reduced pulmonary function in patients with sarcoidosis. In the study 
(5), TIMP-1 was increased in sputum of sarcoidosis patients, but with marginal 
significance. It is estimated that cellular source of MMP-9 and TIMP-1 may primarily 
be multinucleate giant cells localized in sarcoid granuloma, but also macrophages and 
epithelioid cells (7). 
It has been considered that MMP-9/TIMP-1 complex represents the functionality 
of antiproteases system. Increased levels of MMP-9 bound to TIMP-1 are usually 
followed by increased TIMP-1 concentrations and indicate greater efficiency of TIMP-1 
in neutralizing MMP-9 (8). MMP-9/TIMP-1 complex concentrations have been 
documented in patients with neutrophilic and eosionophilic asthma (8) and in chronic 
obstructive pulmonary disease (COPD) (9). Neutrophilic asthma having higher TIMP-1 
concentration than eosinophilic asthma was also characterized by higher MMP-9/TIMP-
1 complex (8). The study on the patients with COPD reported  increased levels of 
MMP-9/TIMP-1 complex in exacerbation state of disease when compared with stable 
state or control subjects. However, to our knowledge, there are still no data describing 
MMP-9/TIMP-1 complex in sarcoidosis. 
MMP-9/TIMP-1 ratio indicates a shift in the balance between the enzyme and its 
inhibitor in favour of MMP-9. It means that ratio would be increased in the state of 
increased proteases activity (4). Previous studies (4, 5) showed increased levels of this 
parameter in sarcoidosis patients when compared with controls although significant 
difference was not found in the study (4). 
The aim of our study was to evaluate MMP-9, TIMP-1 and MMP-9/TIMP-1 




relationship with inflammatory markers and their ability do predict the existence of 
disease.  
Materials and methods 
Subjects 
In this study, we included 101 sarcoidosis patients from the Clinic for Pulmonary 
Diseases and Tuberculosis, Clinical Centre of Serbia, Belgrade. The diagnosis was 
established by clinical, radiological and histological findings (10). Patients underwent 
biopsy analysis that confirmed noncaseating epithelioid granulomatous inflammation in 
the appropriate organ/tissue. Other non-infectious and infectious causes of granulomas 
had been excluded. The exclusion criteria for the patients were the presence of 
cardiovascular disease, pulmonary (any other pulmonary disease except sarcoidosis), 
neurological, renal, hepatic, endocrine or malignant disease. Among patients, 84 were 
prescribed prednisolone, 14 were prescribed prednisolone together with methotrexate 
and 3 were received only methotrexate. Low daily dose of prednisolone was applied 
(median: 10 mg; interquartile range: 5-10 mg) whereas methotrexate was applied 
weekly (median: 5 mg; interquartile range: 5-10 mg).We also included 50 healthy 
subjects who were at their regular medical check-up at the local health center and 
accepted the participation in this study. The inclusion criteria for controls were the 
absence of any pulmonary, gastrointestinal, hepatic, renal, cardiovascular, malignant or 
endocrine disease.The study was planned according to the ethical guidelines stated in 
the Helsinki declaration. Written informed consent was obtained from all subjects prior 
to study entry. The research was approved by the institutional committee (Ethics Board) 
of Clinical Centre of Serbia. 
Sample collection 
After a 12-hour fasting period, venous blood samples were collected into serum 
sample tubes and then centrifuged (1500xg, 10 min at 40C) to obtain serum. Samples 
were aliquoted and stored at -800C. Aliquots were thawed immediately before analyses. 
Biochemical parameters 
Concentration of serum glucose, total protein, albumin, total calcium, urea, 
creatinine and uric acid as well as activity of alkaline phosphatase were assayed by 
routine laboratory methods (ILAB 300+analyzer, Instrumentation Laboratory, Milan, 
Italy). The latex-enhanced immunoturbidimetry method (Quantex hsCRP kit, BIOKIT, 
Barcelona, Spain) was used to measure the concentration of high-sensitive C-reactive 
protein (hsCRP) on an ILAB 600 analyzer. ACE was determined by commercially 
available colorimetric method (Fujirebio Diagnostics Inc.) with p-hydroxybenzoyl-
glycyl-L-hystidyl-L-leucine as a substrate.The concentration of serum amyloid A 




immunosorbent assay (ELISA) kit (Immunology Consultants Laboratory, Portland, OR, 
USA). 
MMP-9, TIMP-1 and MMP-9/TIMP-1 complex concentrations were measured by 
commercially available enzyme-linked immunosorbent assay (ELISA) kits (Research 
and Diagnostics Systems, Minneapolis, MN, USA). The intra- and inter-assay 
coefficients of variation (CV) were as follows: 1.9% and 7.8% for MMP-9, 3.9% and 
3.9% for TIMP-1, and 2.6% and 4.5% for MMP-9/TIMP-1 complex. MMP-9/TIMP-1 
ratio was calculated. 
Statistical analysis 
To describe the data, we used means±standard deviation for normally-distributed 
data, geometric means and 95% confidence intervals for log-transformed normally-
distributed data, median and interquartile range for non-normally distributed data and 
absolute frequencies for categorical variables. The normality of distribution of 
parameters was assessed using the Kolmogorov Smirnov test. Continuous variables 
having normal or log-normal distribution were compared using Student’s t-test. The 
Mann Whitney test was used for comparisons of non-normally-distributed data. 
Differences between categorical variables were tested with Chi-square test for 
contingency tables. Spearman's correlation analysis was employed to determine possible 
correlations between examined parameters. The ability of parameters to predict disease 
was estimated using binary logistic regression analysis. All statistical analyses were 
performed using MS Excel, PASW Statistics Version 18.0 and MedCalc (version 11.4 
Software, Belgium) software. The 0.05 probability level was considered significant in 
all statistical tests. 
 
Results 
Demographic and biochemical parameters of sarcoidosis patients and control 
group are given in Table 1. Patients and controls were matched according to age and 
gender. The concentrations of glucose, urea and creatinine were significantly lower 
whereas the concentrations of total proteins and albumin were significantly higher in 
patients group when compared to controls. HsCRP and SAA were significantly 










Table I  Basic biochemical characteristics and inflammatory parameters of sarcoidosis patients  
                  and control group 
 
Parameter Controls (N=50) 
Sarcoidosis 
(N=101)  Pc 
Age (years) 47.3 ± 9.4 51.0 ± 10.9 0.057 
Gender (m/f) 20/30 32/69  0.406d 
Glucose (mmol/L)  b5.2 (4.8-5.5) 4.9 (4.5-5.6) 0.031 
Urea (mmol/L) 6.21 ± 1.41 5.56 ± 1.56 0.015 
Creatinine (μmol/L) 86.7 ± 12.0 81.5 ± 13.4 0.030 
Uric acid (μmol/L) 344 ± 93 291 ± 86 <0.001  
Total proteins (g/L) 69.1 ± 5.2 72.3 ± 5.1 <0.001 
Albumin (g/L) 35.1 ± 1.5 43.2 ± 3.0 ˂0.001 
Calcium (mmol/L) / 2.35 ± 0.10 / 
Alkaline phosphatase 
(U/L) / 73.9 ± 23.5 / 
hsCRP (mg/L)  a0.97 (0.75-1.24) 2.05 (1.63-2.56) ˂0.001 
ACE (U/L) / b53.0 (42.0‐67.0) / 
SAA (μg/mL)  a2.64 (1.96-3.55) 9.94 (7.57-13.05) ˂0.001 
a – geometric mean and  95% confidence interval, 
b – median and interquartile range 
c – Student t-test, d – Chi square test 
 
Results obtained for protease/antiprotease system are presented in Table 2. The 
concentrations of MMP-9 and TIMP-1 were significantly higher in sarcoidosis patients 
when compared with those obtained for controls. MMP-9/TIMP-1 complex was higher 
in patients, but with marginal significance. The ratio of MMP-9/TIMP-1 was lower in 









Table II   MMP-9, TIMP-1 and MMP-9/TIMP-1 complex concentrations and ratio  
  MMP-9/TIMP-1 in sarcoidosis patients and controls 
 
Parameter Controls Sarcoidosis  Pb 
MMP-9 (ng/mL)  a131.2 (109.5-152.0) 172.3 (152.3-195.3) 0.010 
TIMP-1 (ng/mL) 143.0 ± 49.3 229.4 ± 104.3 ˂0.001 
MMP-9/TIMP-1 
complex (ng/mL)  a1.14 (0.74-1.75) 1.80 (1.39-2.34) 0.062 
MMP-9/TIMP-1 
ratio 
a0.974 (0.817-1.160) 0.829 (0.733-0.938) 0.140 
a – geometric mean and 95% confidence interval,  
b – Student t-test 
 
We performed Spearman’s correlation analysis to test associations of MMP-9, 
TIMP-1, MMP-9/TIMP-1 complex and MMP-9/TIMP-1 ratio with ACE, hsCRP and 
SAA in sarcoidosis and controls. In sarcoidosis, TIMP-1 correlated significantly 
positively with all mentioned inflammatory parameters and MMP-9/TIMP-1 ratio was 
in inverse association with ACE. These results are given in Table 3. In control group, no 
significant associations were found between protease/antiprotease and inflammatory 















Table III Association ofMMP-9, TIMP-1 and MMP-9/TIMP-1 complex concentrations and   
ratio MMP-9/TIMP-1 with inflammatory parameters in sarcoidosis patients  
 
Parametera ACE (U/L) hsCRP (mg/L) SAA (μg/mL) 
MMP-9 (ng/mL) -0.001 0.118 0.046 
TIMP-1 (ng/mL) 0.452** 0.216* 0.330* 
MMP-9/TIMP-1 
complex (ng/mL) -0.034 0.066 0.088 
MMP-9/TIMP-1 ratio -0.248* 0.083 -0.099 
a – Spearman correlation coefficient, *P<0.05; **P<0.01 
 
In order to determine whether the measurement of protease/antiprotease and 
inflammatory parameters had the potential to predict disease, we used binary logistic 
regression analysis. In the uni-variate analysis, MMP-9, TIMP-1, hsCRP and SAA 
showed the ability to predict the existence of sarcoidosis. These results are presented in 
Table IV. However, when each of these parameters (MMP-9, TIMP-1, hsCRP and 
SAA) adjusted for the parameters presented in Table IV, only SAA remained significant 















Table IV Binary logistic regression analysis of risk potentials for protease/antiprotease system 
and inflammatory markers 
 
Parameter OR 95% CI P 
MMP-9 (ng/mL) 1.003 1.000-1.007 0.041 
TIMP-1 (ng/mL) 1.015 1.009-1.022 0.000 
MMP-9/TIMP-1 
complex (ng/mL) 1.060 0.971-1.158 0.195 
MMP-9/TIMP-1 
ratio 0.912 0.664-1.252 0.568 
hsCRP (mg/L) 1.523 1.185-1.957 0.001 
SAA (μg/mL) 1.252 1.066-1.469 0.006 
The dependent variable was disease status sarcoidosis (1) comparing to control (0)  
 
Discussion 
In our current study, we found that concentrations of hsCRP, SAA (Table I), 
MMP-9 and TIMP-1 (Table II) were significantly higher in sarcoidosis when compared 
with controls. TIMP-1 correlated significantly with all mentioned inflammatory markers 
(Table III). HsCRP, SAA, MMP-9 and TIMP-1 showed the potential to predict 
sarcoidosis (Table IV), but only SAA in multivariate analysis remained significant 
predictor of disease. 
As sarcoidosis is an inflammatory disease, it has been expected to observe 
increased values of hsCRP, ACE (11, 12) and SAA compared to controls (13, 14) and 
our results were in agreement with these findings (Table I). Increased concentrations of 
SAA may be a consequence of either increased production of proinflammatory 
cytokines that stimulate hepatic production of SAA (11) or activated cells in 
granulomas that also produce SAA (15). 
Our result of significantly increased concentration of MMP-9 in sarcoidosis 
comparing to controls (Table II) may be due to the inflammatory processes that are 
associated with protease/antiprotease imbalance (2). It has been documented that 
multinucleate giant cells and macrophages found in granulomas (2, 4, 7) and epithelial 




remodeling. Henry et al (4) and Fireman et al (5) found that MMP-9 levels were 
increased in BAL fluid and induced sputum of sarcoidosis patients. MMP expression 
may be upregulated by increased production of proinflammatory cytokines (2). 
Additionally, it has been reported that SAA may induce MMP production in synovial 
fibroblasts of patients with rheumathoid arthritis (16, 17) and our finding of increased 
MMP-9 could be also supported by increase in SAA concentration.  
We found significantly higher levels of TIMP-1 in sarcoidosis than in controls 
(Table II) and TIMP-1 showed significant positive associations with inflammatory 
parameters (Table III). In the study of Fireman et al (5), it was shown that TIMP-1 was 
higher in sarcoidosis than in controls, but with marginal significance. Nevertheless, 
Shimada et al (6) observed significantly increased concentrations of TIMP-1 in 
sarcoidosis patients with stage 2 when compared with patients in stage 1. This suggests 
that more pronounced inflammation occuring in stage 2 may contribute to higher levels 
of TIMP-1. Similar result of highest TIMP-1 concentration in sarcoidosis patients with 
stage 3 when compared with those in stage 1 and 2 (4) may additionally confirm the 
influence of inflammation on ECM proteins. The sources of TIMP-1 have been 
considered to be lymphocytes (18) and macrophages (19). Previous report (6) revealed 
that MMP-9 concentration and MMP-9/TIMP-1 ratio were not altered significantly by 
the stage of disease indicating that TIMP-1 may be more sensitive to inflammation than 
MMP-9. In this study, it was also shown that only TIMP-1 correlated significantly with 
vital capacity of the lung. Capacity of the lung can be infuenced by inflammation (6) 
and this could be an explanation for significant correlations obtained only between 
TIMP-1 and inflammatory parameters in our study. However, Piotrowski et al (20) 
found no significant correlations between neither MMP-9 nor TIMP-1 with lung 
function parameters. 
According to our knowledge, the current study was the first to demonstrate the 
concentrations of MMP-9/TIMP-1 complex in sarcoidosis which was higher than in 
controls, but with marginal significance (Table II). On the other hand, MMP-9/TIMP-1 
ratio was lower in patients than in controls with no significance (Table II).The complex 
is considered to represent functionality of antiproteases (8) whereas the ratio shows the 
balance between protease and antiprotease in favour of protease activity (4). Increased 
levels of MMP-9 bound to TIMP-1 are usually followed by increased TIMP-1 
concentrations and indicate greater efficiency of TIMP-1 in neutralizing MMP-9 (8). 
The same authors (8) demonstrated that neutrophilic asthma having higher TIMP-1 
concentration than eosinophilic asthma was also characterized by higher MMP-9/TIMP-
1 complex. Our patients also had higher TIMP-1 concentration than controls with higher 
MMP-9/TIMP-1 complex. Previous study (9) on COPD patients also described 
increased levels of MMP-9/TIMP-1 complex in exacerbation state of disease when 




difference of MMP-9/TIMP-1 ratio in sarcoidosis was in accordance with the result 
obtained in the study of Henry and coworkers (4) where MMP-9/TIMP-1 ratios in 
sarcoidosis patients having less severe stages of disease did not differ significantly from 
healthy subjects. 
We found that MMP-9 and TIMP-1 as well as hsCRP and SAA in univariate 
binary logistic analysis were able to predict sarcoidosis (Table IV). In the model 
consisted of variables listed in Table IV, it was shown that only SAA was the marker 
which significantly predict disease. The result showed that although MMP-9 and TIMP-
1 were important in disease prediction and progression, the significance of SAA as a 
marker of granulomatous inflammation (15) was higher than the significance of matrix 
metalloproteinases and their tissue inhibitors. It has been documented that SAA induce 
transcription of MMPs mRNA (16, 17, 21) suggesting the importance of this molecule 
in regulating protease/antiprotease system and this was probably the reason why only 
SAA in multivariate analysis showed significant potential in sarcoidosis prediction. 
In conclusion, we found significantly increased levels of MMP-9 and TIMP-1 in 
sarcoidosis patients. TIMP-1 correlated significantly with inflammatory parameters. 
MMP-9 and TIMP-1 had the potential to predict sarcoidosis, but only SAA retained this 
ability in multivariate analysis. 
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Kratak sadržaj 
Matriks metaloproteinaze (MMP) i tkivni inhibitori matriks metaloproteinaza  (TIMP) 
imaju značajnu ulogu u destrukciji plućnog ekstracelularnog matriksa. Sarkoidoza je 
inflamatorno oboljenje koje zahvata različite organe. Utvrđeno je da su koncentracije MMP-9 i 
TIMP-1 povećane u bronhoalveolarnom lavatu i sputumu pacijenata sa sarkoidozom. Cilj naše 
studije je bio da se odrede koncentracije MMP-9, TIMP-1 i MMP-9/TIMP-1 kompleksa, MMP-
9/TIMP-1 odnosa u sarkoidozi, njihova povezanost sa parametrima inflamacije, kao i njihov 
potencijal za predviđanje postojanja bolesti. Ispitivanjem su obuhvaćeni 101 pacijent sa 
sarkoidozom i 50 zdravih ispitanika. Analizirani su uzorci seruma. Pored rutinskih biohemijskih 
parametara, merene su koncentracije visoko-osetljivog C-reaktivnog proteina (hsCRP), 
serumskog amiloida A (SAA), MMP-9, TIMP-1 i MMP-9/TIMP-1 kompleksa. MMP-9 
(P<0,05), hsCRP, SAA i TIMP-1 (P<0,001) su bili značajno veći kod pacijenata dok je 
koncentracija MMP-9/TIMP-1 kompleksa bila veća, ali sa graničnom značajnošću. U 
sarkoidozi, TIMP-1 je značajno pozitivno korelirao sa inflamatornim parametrima (P<0,05). 
Uni-varijantna analiza je pokazala da su MMP-9, TIMP-1, hsCRP i SAA imali značajan 
potencijal za predviđanje postojanja bolesti. U modelu koji je sadržao MMP-9, TIMP-1, hsCRP 
i SAA, samo SAA je ostao značajan u ovom predviđanju (P<0,01). Rezultati pokazuju značaj 
MMP-9 i TIMP-1 u sarkoidozi. 
 
Ključne reči:  sarkoidoza; matriks metaloproteinaza-9;  
tkivni inhibitor matriks metaloproteinaza-1; inflamacija 
 
 
